2009
Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder
Landeros-Weisenberger A, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, Pittenger C, Krystal JH, Goodman WK, Leckman JF, Coric V. Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder. Journal Of Affective Disorders 2009, 121: 175-179. PMID: 19577308, PMCID: PMC3974618, DOI: 10.1016/j.jad.2009.06.010.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderSRI responseSymptom dimensionsOpen-label continuation phaseClinical Global Improvement ScaleGlobal Improvement ScaleCentral serotonin systemInitial positive responseYale-Brown ObsessiveContinuation phaseMinor symptomsOrdinal logistic regressionClinical trialsSerotonin systemTreatment responseSame patientImprovement ScaleSRI treatmentPatientsSignificant associationLogistic regressionCompulsive ScaleOCD patientsOCD subjectsSymptoms
1995
Effects of tryptophan depletion on responses to yohimbine in healthy human subjects
Goddard A, Charney D, Germine M, Woods S, Heninger G, Krystal J, Goodman W, Price L. Effects of tryptophan depletion on responses to yohimbine in healthy human subjects. Biological Psychiatry 1995, 38: 74-85. PMID: 7578653, DOI: 10.1016/0006-3223(94)00223-p.Peer-Reviewed Original ResearchConceptsHealthy human subjectsTryptophan depletionAlpha-2 adrenergic antagonist yohimbinePlacebo-controlled challenge testHuman subjectsAntagonist yohimbineNeurotransmitter systemsSerotonin systemChallenge testPossible functional interactionBiochemical variablesWhole groupFeelings of nervousnessNE functionMarked increaseNorepinephrineConsiderable evidenceFear responsesSubjectsHuman anxietyNervousnessCombination testControl testsFunctional interactionUnique changes